AONC Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 60.18%, SMA50 68.36%, SMA200 -36.44%). The stock’s 14-day RSI is 65.7 (firm momentum), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -92.45% below its high and over 196.04% above its low. Average 10-day trading volume of 577.50 shares is significantly above the 3-month average of 205.38, indicating heightened recent market interest.

American Oncology Network, Inc. has 29.25 million shares outstanding. The public float is 10.26 million shares, elevated short interest at 0.39% of float. This equals 10.81 thousand shares. The short ratio is 0.63 days. Institutional investors hold 0.38% of the float. Insiders own 77.92%. Divers Stephen holds 62.47 thousand shares, Schonherz Todd has 4.00 thousand shares and Saba Capital Management, L.P. has 0.00 shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

American Oncology Network, Inc. (OTC:AONC) closed at $12.20 USD, gaining $2.21 (22.12%) from the previous close of $9.99. The stock is currently mid-range between its 52-week high and low $0.00 and $14.25. With a market capitalization of about $356.83 million, American Oncology Network, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.52). Key stats such as the average daily volume over the past year has been around 759.00 shares, volume is running light vs its 52-week average. Headquartered in Fort Myers, FL, American Oncology Network, Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Todd Schonherz, the company employs approximately 1,914 people and listed since July 09, 2024. American Oncology Network, Inc. engages in the provision of community-based oncology management.

American Oncology Network, Inc. trades at a P/E ratio of -17.68, slightly below the S&P 500 average, with a price-to-sales ratio of 0.2 and a price-to-book ratio of 8.92 trading at moderately above to book value. The P/FCF stands at -13.78, also below market averages.

Our AI price prediction model suggests that American Oncology Network, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.74%, with price expected at $12.29 by August 27, 2026, within a range of $10.56 to $14.03 3-Month Outlook: Projected fall of -9.26%, reaching $11.07 by November 11, 2026, with a range of $10.80 to $11.35. 1-Year Outlook: Projected gain of 72.05%, with price at $20.99 by August 13, 2027, within a range of $15.26 to $24.32.

currently trading near 52-week highs band. Valuation shows American Oncology Network, Inc. trading at a premium to the broader market with a P/E of -17.68. Our AI forecast model points to short-term strength (0.74% over two weeks), a medium-term fall (-9.26% over three months), and a longer-term gain (72.05% over one year), with expected trading ranges indicating moderate volatility.